Further investigation is needed to unravel the oncogenic networks involving MTF2, PHF19, and WDR26 in myeloma, as this could reveal novel opportunities for targeted molecular treatments and prevention strategies. The gene discussed is WDR26; the disease is plasma cell myeloma.